Mantle cell lymphoma: an update on management

• Published in: Annals of oncology Vol. 17; no. suppl-4; pp. iv12 - iv14
• Main Author: Zelenetz, A D
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.05.2006; Oxford Publishing Limited (England)
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; autologous stem cell transplantation; bortezomib; Combined Modality Therapy; flavopiridol; Humans; Lymphoma, Mantle-Cell - therapy; mantle cell lymphoma; Radioimmunotherapy; rituximab; Stem Cell Transplantation; targeted therapies; temsirolimus
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdj992

Although response rates are increased, the addition of rituximab to induction chemotherapy has not yet been proven to extend the progression-free and overall survival benefits of chemotherapy alone. In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate does not reach a plateau. Radioimmunotherapy has substantial single-agent activity and when combined with chemotherapy may provide a platform onto which rituximab or autologous stem cell transplantation can be added. Targeted therapies are also showing promise and may have a role in maintenance and/or initial therapy.